Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...
Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...
One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...
The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...
CLEVELAND, Ohio — Eggs are disappearing from store shelves due to shortages caused by the avian flu outbreak, but never fear ...
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results